

83605

STIC-Biotech/ChemLib

From: Chan, Christina  
Sent: Sunday, January 05, 2003 11:47 AM  
To: Canella, Karen; STIC-Biotech/ChemLib  
Subject: RE: rush search request for 09/855,158

Please rush. Thanks Chris

Chris Chan  
TC 1600 New Hire Training Coordinator and SPE 1644  
308-3973  
CM-1, 9B19

-----Original Message-----

From: Canella, Karen  
Sent: Friday, January 03, 2003 9:37 PM  
To: Chan, Christina  
Subject: rush search request for 09/855,158

Chris,  
Could you please authorize the following rush search for 09/855,158? It's an amended case due this bi-week.  
Thanks,  
Karen

Search and Interference Search

In the Protein Databases, the following peptides:  
1. SEQ ID NO:6, 7, 13, 15 and 16

Karen Canella  
office 9E17  
mail 8E12  
308-8362

POINT OF CONTACT:  
PAUL SCHULWITZ  
TECHNICAL INFO. SPECIALIST  
CM1 6B06 TEL. (703) 305-1954

Searcher: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Location: \_\_\_\_\_  
Date Picked Up: 1/6  
Date Completed: 1/8  
Searcher Prep/Review: \_\_\_\_\_  
Clerical: \_\_\_\_\_  
Online time: \_\_\_\_\_

TYPE OF SEARCH:  
NA Sequences: \_\_\_\_\_  
AA Sequences: \_\_\_\_\_  
Structures: \_\_\_\_\_  
Bibliographic: \_\_\_\_\_  
Litigation: \_\_\_\_\_  
Full text: \_\_\_\_\_  
Patent Family: \_\_\_\_\_  
Other: \_\_\_\_\_

VENDOR/COST (where applic.)  
STN: \_\_\_\_\_  
DIALOG: \_\_\_\_\_  
Questel/Orbit: \_\_\_\_\_  
DRLink: \_\_\_\_\_  
Lexis/Nexis: \_\_\_\_\_  
Sequence Sys.: \_\_\_\_\_  
WWW/Internet: \_\_\_\_\_  
Other (specify): \_\_\_\_\_

L31 ANSWER 1 OF 1 MEDLINE on STN  
 ACCESSION NUMBER: 97477906 MEDLINE  
 DOCUMENT NUMBER: 97477906 PubMed ID: 9336839  
 TITLE: Ligand binding to proteins: the binding landscape model.  
 AUTHOR: Miller D W; Dill K A  
 CORPORATE SOURCE: Graduate Group in Biophysics, University of California at  
 San Francisco 94143-1204, USA.  
 SOURCE: PROTEIN SCIENCE, (1997 Oct) 6 (10)  
 2166-79.  
 Journal code: 9211750. ISSN: 0961-8368.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 199802  
 ENTRY DATE: Entered STN: 19980306  
 Last Updated on STN: 19980306  
 Entered Medline: 19980220

AB Models of ligand binding are often based on four assumptions: (1) steric fit: that binding is determined mainly by shape complementarity; (2) native binding: that ligands mainly bind to native states; (3) locality: that ligands perturb protein structures mainly at the binding site; and (4) continuity: that small changes in ligand or protein structure lead to small changes in binding affinity. Using a generalization of the 2D HP lattice model, we study ligand binding and explore these assumptions. We first validate the model by showing that it reproduces typical binding behaviors. We observe ligand-induced denaturation, ANS and heme-like binding, and "lock-and-key" and "induced-fit" specific binding behaviors characterized by Michaelis-Menten or more cooperative types of binding isotherms. We then explore cases where the model predicts violations of the standard assumptions. For example, very different binding modes can result from two ligands of identical shape. Ligands can sometimes bind highly denatured states more tightly than native states and yet have Michaelis-Menten isotherms. Even low-population binding to denatured states can cause changes in global stability, hydrogen-exchange rates, and thermal B-factors, contrary to expectations, but in agreement with experiments. We conclude that ligand binding, similar to protein folding, may be better described in terms of energy landscapes than in terms of simpler mass-action models.

L18 ANSWER 2 OF 3

MEDLINE

DUPLICATE 2

ACCESSION NUMBER:

1998066445 MEDLINE

DOCUMENT NUMBER:

98066445 PubMed ID: 9398215

TITLE:

Determination of tumor necrosis factor binding protein disulfide structure: deviation of the fourth domain structure from the TNFR/NGFR family cysteine-rich region signature.

AUTHOR:

Jones M D; Hunt J; Liu J L; Patterson S D; Kohno T; Lu H S

CORPORATE SOURCE:

Department of Protein Structure, Amgen Inc., Amgen Center, Thousand Oaks, California 91320, USA.

SOURCE:

BIOCHEMISTRY, (1997 Dec 2) 36 (48) 14914-23.  
Journal code: 0370623. ISSN: 0006-2960.

PUB. COUNTRY:

United States

DOCUMENT TYPE:

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE:

English

FILE SEGMENT:

Priority Journals

ENTRY MONTH:

199801

ENTRY DATE:

Entered STN: 19980122

Last Updated on STN: 20000303

Entered Medline: 19980108

AB Tumor necrosis factor binding protein is a soluble molecule derived from the extracellular domain of the 55 kDa human tumor necrosis factor receptor, which can block the biological function of tumor necrosis factor

by **binding** to the growth factor. This **cysteine-rich** molecule is subdivided into four domains, each containing six conserved cysteines that form three intrachain disulfide linkages known as

the **tumor necrosis factor** receptor/nerve growth factor receptor **family** cysteine-rich region signature structure. In an effort to elucidate the molecular integrity of the molecule, we performed detailed analysis and searched for strategies to elucidate the complete disulfide structure of the E. coli-derived tumor necrosis factor binding protein and to determine the disulfide arrangement in the fourth domain of Chinese hamster ovary cell-derived molecule. The methods employed included various proteolytic digestions, peptide mapping, partial reduction, and assignment of disulfides by N-terminal sequencing and matrix-assisted laser desorption ionization mass spectrometry with post-source decay. The first three domains of the molecule were confirmed to have disulfide structures identical to the cysteine-rich region signature structure found in the above-mentioned receptor superfamily.

The

fourth domain has a different structure from the first three domains where

the last four cysteines form two disulfide bonds in opposite positions.

L1 ANSWER 1 OF 1 MEDLINE  
 ACCESSION NUMBER: 2000259066 MEDLINE  
 DOCUMENT NUMBER: 20259066 PubMed ID: 10801128  
 TITLE: TACI and BCMA are receptors for a TNF homologue implicated  
 in B-cell autoimmune disease.  
 COMMENT: Comment in: Nature. 2000 Apr 27;404(6781):949-50  
 AUTHOR: Gross J A; Johnston J; Mudri S; Enselman R; Dillon S R;  
 Madden K; Xu W; Parrish-Novak J; Foster D; Lofton-Day C;  
 Moore M; Littau A; Grossman A; Haugen H; Foley K; Blumberg  
 H; Harrison K; Kindsvogel W; Clegg C H  
 CORPORATE SOURCE: Department of Immunology, ZymoGenetics, Seattle,  
 Washington  
 SOURCE: 98102, USA.. grossj@zgi.com  
 NATURE, (2000 Apr 27) 404 (6781)  
 995-9.  
 Journal code: 0410462. ISSN: 0028-0836.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200005  
 ENTRY DATE: Entered STN: 20000606  
 Last Updated on STN: 20010716  
 Entered Medline: 20000525

AB B cells are important in the development of autoimmune disorders by  
 mechanisms involving dysregulated polyclonal B-cell activation,  
 production  
 of pathogenic antibodies, and co-stimulation of autoreactive T cells.  
 zTNF4 (BLyS, BAFF, TALL-1, THANK) is a member of the tumour necrosis  
 factor (TNF) ligand family that is a potent co-activator of B cells in  
 vitro and in vivo. Here we identify two receptors for zTNF4 and  
 demonstrate a relationship between zTNF4 and autoimmune disease.  
 Transgenic animals overexpressing zTNF4 in lymphoid cells develop  
 symptoms  
 characteristic of systemic lupus erythaematosus (SLE) and expand a rare  
 population of splenic B-1a lymphocytes. In addition, circulating zTNF4 is  
 more abundant in NZBWF1 and MRL-lpr/lpr mice during the onset and  
 progression of SLE. We have identified two TNF receptor family members,  
 TACI and BCMA, that bind zTNF4. Treatment of NZBWF1 mice with soluble  
 TACI-Ig fusion protein inhibits the development of proteinuria and  
 prolongs survival of the animals. These findings demonstrate the  
 involvement of zTNF4 and its receptors in the development of SLE and  
 identify TACI-Ig as a promising treatment of autoimmune disease in  
 humans.